Navigation Links
A new genre of diagnostic tests for the era of personalized medicine
Date:7/26/2012

A new genre of medical tests which determine whether a medicine is right for a patient's genes are paving the way for increased use of personalized medicine, according to the cover story in the current edition of Chemical & Engineering News. C&EN is the weekly newsmagazine of the American Chemical Society, the world's largest scientific society.

Celia Henry Arnaud, C&EN senior editor, points out that the U.S. Food and Drug Administration has approved several precedent-setting cancer drugs that provide a glimpse of the "personalized" medical care that awaits patients with cancer and other diseases in the future. Personalized medicine involves selecting treatments that work best with the set of genes present in each individual person. Such treatments work only for patients with conditions related to mutations, or alterations, in certain genes.

The article describes new "companion diagnostics," or diagnostic tests that already have gone into use, with more on the horizon, to identify patients most likely to benefit from a medication. Doctors must perform these tests before starting treatment. Arnaud describes how pharmaceutical companies are embracing an approach that involves co-development of drugs and companion diagnostics that can be used in clinical trials and later when a medication goes into general use.


'/>"/>

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
Source:Eurekalert

Page: 1

Related medicine news :

1. Diagnostic Scans Tied to Radiation Risk for Gastro Patients
2. Autism by the numbers: Yale researchers examine impact of new diagnostic criteria
3. Diagnostic yield of colonoscopy for melena after nondiagnostic upper endoscopy is lower than previously reported
4. Range of diagnostic spinal fluid tests needed to differentiate concurrent brain diseases
5. Screening for breast cancer without X-rays: Lasers and sound merge in promising diagnostic technique
6. A marker in the lining of the lungs could be useful diagnostic technique for lung cancer screening
7. UGA researchers develop rapid diagnostic test for pathogens, contaminants
8. AMA adopts diagnostic ultrasound utilization and education resolution
9. Physician Groups Call for Fewer Medical Tests
10. URMC clinical trial tests new regimen for hypertension
11. Smell Tests Dont Predict Alzheimers, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014 TCG, a leading government technology strategy ... one of the fastest-growing companies in America for the seventh ... was previously recognized in 2013, 2012, 2011, 2010, 2009, 2008, ... grown 86% from 2010 to 2013, ranking the company at ... in America - up 635 spots from 2013! More information ...
(Date:9/2/2014)... The Wm. Jennings Bryan Dorn Veterans Affairs ... hall meeting for Veterans and their families on September 24. ... to provide Veterans with valuable healthcare and benefit information,” said ... provide a forum where we can gather important input directly ... fair will be held 4:45 p.m. to 5:45 p.m. in ...
(Date:9/2/2014)... California, the percentage undergoing a double mastectomy increased substantially ... associated with a lower risk of death than breast-conserving ... September 3 issue of JAMA . The authors ... breast was associated with a higher risk of death ... Randomized trials have demonstrated similar survival for patients with ...
(Date:9/2/2014)... September 02, 2014 Medex Analytic ... of their corporate headquarters in Coral Springs, Fla. due ... exceeded our business development objectives for the 2014 year ... Herbst. “Our industry has requested a higher level of ... reviews. Medex has delivered, and the industry has responded.” ...
(Date:9/2/2014)... 2014 (HealthDay News) -- Two new studies further confirm ... 6-year-olds who were breast-fed have a lower risk of ... while the other finds a similar trend when it ... benefits of breast-feeding in the immediate newborn period," said ... in New York City. She was not involved in ...
Breaking Medicine News(10 mins):Health News:TCG One of the Fastest-Growing Companies in America – for the Eighth Time! 2Health News:Increase seen in use of double mastectomy 2Health News:Increase seen in use of double mastectomy 3Health News:Medex Analytic Services Announces New Location for Corporate Headquarters 2Health News:More Evidence Breast-Feeding Lowers Child's Risk of Infections, Allergies 2
... CareBETHESDA, Md., March 18 The Cystic Fibrosis Foundation ... leadership in improving the quality of care for people ... Quality Assurance (NCQA).The outlook for people with CF continues ... by the Foundation. In the 1950s, few children with ...
... 18 Medivation, Inc. (Nasdaq: MDVN ... permission from the U.S. Food and Drug Administration ... of MDV3100, its novel androgen receptor antagonist, in ... have failed docetaxel-based chemotherapy. The placebo-controlled, double-blind, ...
... inkjet printer technology, researchers say , , WEDNESDAY, March 18 ... mussels and printer inkjet technology, researchers say they,ve come ... greater precision, promote faster recovery and reduce scarring. , ... tissue together after a patient has surgery, a team ...
... protection, study finds, , , WEDNESDAY, March 18 (HealthDay News) -- ... glasses of beer or wine a day appear to have ... study suggests. , Moderate drinking has been associated with decreasing ... linked to increasing the risk for some cancers. And though ...
... Underserved by other ProvidersLOS ANGELES, March 18 ... Board: FVRL), which through its wholly-owned operating ... Personal Health Records ("PHRs") ( www.mymedicalrecords.com ) ... ( www.myesafedepositbox.com ), has entered into an ...
... March 18 Shamir Optical Industry Ltd. (Nasdaq: ... of innovative products and technology to the ophthalmic lens ... quarter and year ended December 31, 2008.For the quarter ... to $30.6 million for the fourth quarter of 2007. ...
Cached Medicine News:Health News:Cystic Fibrosis Foundation to Receive Prestigious Health Care Award 2Health News:Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer 2Health News:Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer 3Health News:Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer 4Health News:Mussel-Based Glue May Make Surgery Safer 2Health News:A Little Drink May Be Good for Your Bones 2Health News:A Little Drink May Be Good for Your Bones 3Health News:MMR Information Systems Offers First Bilingual Personal Health Record Through The Latino Coalition 2Health News:MMR Information Systems Offers First Bilingual Personal Health Record Through The Latino Coalition 3Health News:MMR Information Systems Offers First Bilingual Personal Health Record Through The Latino Coalition 4Health News:Shamir Optical Industry Ltd. Reports Fourth Quarter and Year-End 2008 Results 2Health News:Shamir Optical Industry Ltd. Reports Fourth Quarter and Year-End 2008 Results 3Health News:Shamir Optical Industry Ltd. Reports Fourth Quarter and Year-End 2008 Results 4Health News:Shamir Optical Industry Ltd. Reports Fourth Quarter and Year-End 2008 Results 5Health News:Shamir Optical Industry Ltd. Reports Fourth Quarter and Year-End 2008 Results 6Health News:Shamir Optical Industry Ltd. Reports Fourth Quarter and Year-End 2008 Results 7Health News:Shamir Optical Industry Ltd. Reports Fourth Quarter and Year-End 2008 Results 8Health News:Shamir Optical Industry Ltd. Reports Fourth Quarter and Year-End 2008 Results 9
(Date:9/2/2014)... , Sept. 2, 2014  Ameritox SM , the ... Deadly Trend: Prescription Drugs to Heroin," a research report ... heroin abuse, and examines deadly trends that have created ... here . The report is ... patients prescribed opioids. It examines five trends that distinguish ...
(Date:9/2/2014)... September 2, 2014 ... ESC-Kongress 2014 präsentierte GARFIELD-AF-Register bietet einen ... von schlaganfallgefährdeten Patienten in der klinischen ... Daten der nahezu 12.500 ... und unabhängigen Forschungsinitiative zur Untersuchung von ...
(Date:9/2/2014)... , Registry provides new insights ... and treatment satisfaction [ 1 ] ...        (Photo: http://photos.prnewswire.com/prnh/20140902/703596 ... Barcelona, Spain : Daiichi Sankyo today ... events-European Registry in Atrial Fibrillation (PREFER in AF), revealing ...
Breaking Medicine Technology:Ameritox Research Report Reveals Pain Patients' Role in Current Heroin Epidemic 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 3Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 4Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 5Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 6Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 7Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 8Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 9Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 10Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 11One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 2One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 3One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 4One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 5One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 6One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 7One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 8
... VANCOUVER, June 21, 2007 /PRNewswire-FirstCall/ - Biotech,Holdings reports ... diabetes drug its support in an overview of,diabetic ... Diabetes,Hoy, the Diabetic Federation's scientific and medical magazine ... of diabetic drugs, written by Dr. Roberto Cepeda,Gonzalez, ...
... -- Orexigen(TM),Therapeutics, Inc. , a biopharmaceutical company ... disorders with an initial focus,on obesity, today ... its lead obesity product candidate Contrave(TM) and ... fat, serum,cholesterol, and triglycerides) and insulin-resistance. The,findings ...
Cached Medicine Technology:Diabetes drug supported by Mexican Diabetes Federation 2Diabetes drug supported by Mexican Diabetes Federation 3Orexigen Therapeutics to Present Data on Contrave Impact on,Visceral Fat and Insulin Resistance at American Diabetes,Association 67th Scientific Sessions in Chicago June 23 2Orexigen Therapeutics to Present Data on Contrave Impact on,Visceral Fat and Insulin Resistance at American Diabetes,Association 67th Scientific Sessions in Chicago June 23 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: